Stock Taper
SCREENER COMPARE ANY 2 STOCKS
VRCA
VERRICA PHARMACEUTICALS INC.
NASDAQ
$5.69
▲ UP 12.23% (0.62)

KEY STATISTICS

Market Cap$97.75 M
52w High$9.82
52w Low$3.28
Dividend Yield—
Frequency—
P/E-6.94
Volume350.76K
Shares Out.17.18M

COMPANY

LEADERSHIP

Jayson Rieger
CHIEF EXECUTIVE
Jayson Rieger

COMPENSATION 2026

Salary$300,000
Stock Awards$0
Incentive Plan Pay$74,375
All Other Comp.$16,792
Total$741,403

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 15, 2018
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
76

PRICE TARGET

Target High$9.00
Target Low$9.00
Target Median$9.00
Target Consensus$9.00

UPCOMING EARNINGS

DateNov 13, 2026
DayFriday
Rev. Est.$6.41M
NOV
13
FRI

SPLIT RECORD

DATETYPERATIO
2025-07-25Reverse1:10

PRICE

$5.69 ▲ UP 12.23% (+$0.62)
OVERLAYS
$5.00$5.25$5.50$5.759:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM5.69

About Verrica Pharmaceuticals Inc.

https://www.verrica.com ↗

Verrica Pharmaceuticals develops dermatology treatments like VP-102 for molluscum and warts, with ongoing clinical trials and collaborations in Japan and oncology, serving skin disease patients in the U.S.

INDUSTRY

Biotechnology

A PRODUCT VERRICA PHARMACEUTICALS INC. IS KNOWN FOR

YCANTH (cantharidin)
YCANTH (cantharidin)

YCANTH is the FDA-approved, proprietary drug-device combo for precise topical treatment of molluscum contagiosum in adults and children, addressing a significant unmet need in dermatology.

COMPETITORS

COMPETITOR
ARQT COMPARE
DERM COMPARE
KRYS COMPARE
MANE COMPARE
PTHS COMPARE

Revenue by Products

IconPRODUCTQ2-2025Q3-2025Q1-2026Q2-2026
Product$4.53M $3.61M ▼$4.29M ▲$5.09M ▲
License And Collaboration Revenue$8.17M $10.74M ▲$733K ▼$800K ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
17
LISTED HERE
4
RANKED BY POSITION SIZE
VTI
0.00% · 216.4K
IWC
0.01% · 36.7K
DFAS
0.00% · 7.4K
AVTM
0.00% · 481

INSTITUTIONAL OWNERSHIP

SHARES OWNED
81.63%
HOLDERS
62
TOP 12 OF 62 · RANKED BY POSITION SIZE
Armistice Capital, LLC
8.9M sh · $4.71M
Blackrock Inc.
1.1M sh · $8.23M
Caligan Partners LP
923.9K sh · $4.89M
Affinity Asset Advisors, LLC
707.3K sh · $3.74M
Cannell Capital LLC
685.1K sh · $3.62M
Velan Capital Investment Management LP
471.6K sh · $2.49M
Stonepine Capital Management, LLC
353.7K sh · $2.94M
Boothbay Fund Management, LLC
280.7K sh · $2.33M
Dafna Capital Management LLC
173.5K sh · $1.44M
Marshall Wace, Llp
140.5K sh · $743.23K
Geode Capital Management, LLC
138.9K sh · $734.97K
Vanguard Group Inc
138.2K sh · $1.15M

RATINGS SNAPSHOT

Overall rating: D+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
OFFICER: INTERIM CFO
Kirby John J.
Purchase · 5.0K shares
2026-08-18
★
DIRECTOR, OFFICER: CEO AND PRESIDENT
Rieger Jayson
Purchase · 20.0K shares
2026-08-14
★
OFFICER: CMO
Rosenberg Noah L.
Purchase · 2.0K shares
2026-08-18
★
OFFICER: CMO
Rosenberg Noah L.
Purchase · 4.2K shares
2026-08-17

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
Brookline Capital BUY

SECTORS PEERS

PEERPRICE
QTTB$15.03COMPARE
SABS$3.79COMPARE
ANTX$5.58COMPARE
BOLD$2.83COMPARE
NXTC$6.09COMPARE
EVAX$3.01COMPARE
JSPR$0.70COMPARE